MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology, Inc. reported that its Head of Finance, Jeffrey C. Himmelreich, received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.28 per share and expire on April 10, 2036. They were granted under the company’s 2021 Equity Incentive Plan as a compensation award, not an open-market purchase. The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remainder vesting monthly over the following 36 months, and represent Himmelreich’s full reported option position of 30,000 shares after this grant.
MAIA Biotechnology reports that net proceeds from its $33 million March 2026 public common stock offering are expected to fully fund its ongoing pivotal Phase 3 THIO-104 trial of ateganosine in third-line non-small cell lung cancer (NSCLC).
The FDA has granted ateganosine Fast Track designation in this setting. THIO-104 is a global, multicenter, open-label Phase 3 study comparing ateganosine sequenced with a checkpoint inhibitor against chemotherapy in a 1:1 randomization of up to 300 patients, using median overall survival and safety as primary objectives. Interim Phase 3 data are expected next year and may support discussions with the FDA about potential early full commercial approval in third-line NSCLC if results are consistent with prior Phase 2 data.
MAIA Biotechnology, Inc. will hold its 2026 annual stockholders meeting virtually on May 21, 2026 at 10:00 a.m. CT via www.virtualshareholdermeeting.com/MAIA2026. Only holders of the 60,671,491 shares of common stock outstanding as of March 23, 2026 may vote, with one vote per share and a quorum requirement of 30,335,747 votes.
Stockholders will elect two Class I directors and vote on ratifying Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026. The proxy statement also details board structure, committee membership, executive compensation, related-party private placements involving directors and a 5% stockholder, and the company’s equity incentive plans and governance policies.
MAIA Biotechnology, Inc. director Steven M. Chaouki received a grant of stock options for 27,907 shares of common stock on March 31, 2026. The options carry an exercise price of $1.40 per share, vest 100% on the grant date, and are exercisable immediately through March 31, 2036.
MAIA Biotechnology director Ramiro Guerrero received a grant of stock options as equity compensation. He was awarded 27,258 stock options on March 31, 2026 with an exercise price of $1.40 per share, each option representing one share of common stock.
The options were granted under MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan, vest 100% on the grant date, and are exercisable beginning March 31, 2026. Following this grant, Guerrero holds 27,258 stock options directly, with the options scheduled to expire on March 31, 2036.
MAIA Biotechnology, Inc. director Louie Ngar Yee received a grant of stock options for 33,748 shares of common stock. The options were granted on March 31, 2026 at an exercise price of $1.40 per share, vest 100% on the grant date, and are immediately exercisable.
Following this grant, he holds 33,748 stock options directly, which are scheduled to expire on March 31, 2036.
MAIA Biotechnology, Inc. director Cristian Luput received a grant of stock options representing the right to acquire 28,556 shares of common stock. The options were granted on March 31, 2026, with an exercise price of $1.40 per share, vest 100% on the grant date, and are exercisable beginning that day until March 31, 2036. This is a compensation-related award rather than an open-market purchase or sale, and leaves Luput holding 28,556 stock options directly following the transaction.
MAIA Biotechnology, Inc. director Theagene Jean-Manasse received a grant of stock options covering 27,258 shares of common stock. The options have an exercise price of $1.40 per share, vest 100% on the grant date, and are exercisable immediately through March 31, 2036.
MAIA Biotechnology director Stan Smith reported an award of stock options as compensation. On March 31, 2026, an entity associated with him, The Stan V. Smith Trust Dated 1993, received 33,099 stock options under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan.
The options give the right to buy an equal number of shares of common stock at an exercise price of $1.40 per share. They vest 100% on the grant date and are exercisable beginning that day, expiring on March 31, 2036. After this grant, the filing shows 33,099 options indirectly beneficially owned.